Literature DB >> 19046301

PTPN22 allele polymorphisms in 15 Chinese populations.

Z-H Zhang1, F Chen, X-L Zhang, Y Jin, J Bai, S-B Fu.   

Abstract

Protein tyrosine phosphatase non-receptor 22 (PTPN22) is involved in the negative regulation of T-cell responsiveness. Recently, it has been reported that a single nucleotide polymorphism (SNP), C1858T, in the gene PTPN22, encoding Arg620Trp in the lymphoid protein tyrosine phosphatase (LYP), is associated with an increased risk of a number of autoimmune diseases. To study the mutant frequency and polymorphism of PTPN22 in Chinese populations, 1085 individuals from 15 Chinese populations distributing widely from north to south were collected. The genotypes of PTPN22-C1858T were determined by polymerase chain reaction-restriction fragment length polymorphism with the digestion of restriction endonuclease RsaI. Of the 1085 individuals, 31 of whom were heterozygote (PTPN22-1858C/T), the frequency of PTPN22-1858T allele in those tested individuals was 1.43%. Moreover, the frequencies of PTPN22-1858T had significant variance in 15 populations of China (chi(2) = 74.1650, P < 0.01).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19046301     DOI: 10.1111/j.1744-313X.2008.00803.x

Source DB:  PubMed          Journal:  Int J Immunogenet        ISSN: 1744-3121            Impact factor:   1.466


  11 in total

Review 1.  Lymphoid tyrosine phosphatase and autoimmunity: human genetics rediscovers tyrosine phosphatases.

Authors:  Stephanie M Stanford; Tomas M Mustelin; Nunzio Bottini
Journal:  Semin Immunopathol       Date:  2010-03-04       Impact factor: 9.623

Review 2.  Ethnogenetic heterogeneity of rheumatoid arthritis-implications for pathogenesis.

Authors:  Yuta Kochi; Akari Suzuki; Ryo Yamada; Kazuhiko Yamamoto
Journal:  Nat Rev Rheumatol       Date:  2010-03-16       Impact factor: 20.543

3.  Clinical characteristics and PTPN22 1858C/T variant analysis in Jordanian Arab vitiligo patients.

Authors:  Asem Alkhateeb; Firas Qarqaz; Jude Al-Sabah; Tasnim Al Rashaideh
Journal:  Mol Diagn Ther       Date:  2010-06-01       Impact factor: 4.074

4.  NLRP1, PTPN22 and PADI4 gene polymorphisms and rheumatoid arthritis in ACPA-positive Singaporean Chinese.

Authors:  Liuh Ling Goh; Mei Yun Yong; Wei Qiang See; Edward Yu Wing Chee; Pei Qi Lim; Ee Tzun Koh; Khai Pang Leong
Journal:  Rheumatol Int       Date:  2017-06-26       Impact factor: 2.631

5.  Protein Tyrosine Phosphatase Non-receptor 22 Gene C1858T Polymorphism in Patients with Coexistent Type 2 Diabetes and Hashimoto's Thyroiditis.

Authors:  Funda Bulut; Deniz Erol; Halit Elyas; Halil Doğan; Fethi Ahmet Ozdemir; Lezan Keskin
Journal:  Balkan Med J       Date:  2014-03-01       Impact factor: 2.021

6.  Variants in PTPN22 and SMOC2 genes and the risk of thyroid disease in the Jordanian Arab population.

Authors:  Asem Alkhateeb; Nour Al-Dain Marzouka; Reema Tashtoush
Journal:  Endocrine       Date:  2013-03-06       Impact factor: 3.633

7.  No association of PTPN22 polymorphisms with susceptibility to ocular Behcet's disease in two Chinese Han populations.

Authors:  Qi Zhang; Shengping Hou; Zhengxuan Jiang; Liping Du; Fuzhen Li; Xiang Xiao; Aize Kijlstra; Peizeng Yang
Journal:  PLoS One       Date:  2012-03-02       Impact factor: 3.240

8.  The genetic basis of graves' disease.

Authors:  Rafał Płoski; Konrad Szymański; Tomasz Bednarczuk
Journal:  Curr Genomics       Date:  2011-12       Impact factor: 2.236

9.  Protein tyrosine phosphatase non-receptor type 22 gene polymorphism C1858T is not associated with leprosy in Azerbaijan, Northwest Iran.

Authors:  Mohammad Reza Aliparasti; Shohreh Almasi; Jafar Majidi; Fatemeh Zamani; Ali Reza Khoramifar; Ali Reza Farshi Azari
Journal:  Indian J Hum Genet       Date:  2013-10

10.  A functional variant of PTPN22 confers risk for Vogt-Koyanagi-Harada syndrome but not for ankylosing spondylitis.

Authors:  Qi Zhang; Jian Qi; Shengping Hou; Liping Du; Hongsong Yu; Qingfeng Cao; Yan Zhou; Dan Liao; Aize Kijlstra; Peizeng Yang
Journal:  PLoS One       Date:  2014-05-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.